Gerald P Linette
Overview
Explore the profile of Gerald P Linette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
16092
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, et al.
Cancer Cell
. 2025 Feb;
43(3):537-551.e7.
PMID: 39983725
Tumor resistance to chimeric antigen receptor T cell (CAR-T) and, in general, to adoptive cell immunotherapies (ACTs) is a major challenge in the clinic. We hypothesized that inhibiting the tumor...
2.
Bear A, Nadler R, OHara M, Stanton K, Xu C, Saporito R, et al.
J Clin Invest
. 2024 Sep;
134(21).
PMID: 39287991
BACKGROUNDNeoantigens derived from KRASMUT have been described, but the fine antigen specificity of T cell responses directed against these epitopes is poorly understood. Here, we explore KRASMUT immunogenicity and the...
3.
Patel R, Ghilardi G, Zhang Y, Chiang Y, Xie W, Guruprasad P, et al.
Sci Immunol
. 2024 Jul;
9(97):eadn6509.
PMID: 39028827
Most patients treated with US Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid...
4.
Chang J, Wellhausen N, Engel N, Landmann J, Hopkins C, Salas-Mckee J, et al.
Cancer Immunol Res
. 2024 Jun;
12(9):1136-1146.
PMID: 38869428
Genome editing technologies have seen remarkable progress in recent years, enabling precise regulation of exogenous and endogenous genes. These advances have been extensively applied to the engineering of human T...
5.
Linette G, Bear A, Carreno B
Clin Cancer Res
. 2024 Jan;
30(10):2017-2024.
PMID: 38266167
In this commentary, we advance the notion that mutant KRAS (mKRAS) is an ideal tumor neoantigen that is amenable for targeting by the adaptive immune system. Recent progress highlights key...
6.
Lee I, Sharma N, Noguera-Ortega E, Liousia M, Baroja M, Etersque J, et al.
Mol Ther
. 2023 Nov;
31(12):3564-3578.
PMID: 37919903
Chimeric antigen receptor (CAR) T cell therapy has been successful for hematological malignancies. Still, a lack of efficacy and potential toxicities have slowed its application for other indications. Furthermore, CAR...
7.
Shah P, Huang A, Xu X, Orlowski R, Amaravadi R, Schuchter L, et al.
Cancer Res Commun
. 2023 Jun;
3(5):821-829.
PMID: 37377890
Purpose: Treatments are limited for metastatic melanoma and metastatic triple-negative breast cancer (mTNBC). This pilot phase I trial (NCT03060356) examined the safety and feasibility of intravenous RNA-electroporated chimeric antigen receptor...
8.
Smole A, Benton A, Poussin M, Eiva M, Mezzanotte C, Camisa B, et al.
Cancer Cell
. 2022 Dec;
40(12):1470-1487.e7.
PMID: 36513049
Despite the success of CAR-T cell cancer immunotherapy, challenges in efficacy and safety remain. Investigators have begun to enhance CAR-T cells with the expression of accessory molecules to address these...
9.
Garfall A, Cohen A, Susanibar-Adaniya S, Hwang W, Vogl D, Waxman A, et al.
Blood Cancer Discov
. 2022 Nov;
4(2):118-133.
PMID: 36413381
Significance: CAR T cells in early lines of MM therapy could be safer and more effective than in the advanced setting, where prior studies have focused. We evaluated the safety,...
10.
Fracasso P, Goodner S, Wildi J, Naughton M, Linette G, Govindan R, et al.
Am J Clin Oncol
. 2022 Jun;
45(7):294-297.
PMID: 35700081
Background: Human leukocyte antigen (HLA)-DR, a member of the major histocompatibility complex class II antigen family, is a target for antibody-based therapeutics. Apolizumab (Hu1D10, Remitogen), a humanized IgG1 monoclonal anti-HLA-DR...